O utcomes among patients presenting with ST-segmentelevation myocardial infarction (STEMI) and non-STsegment-elevation myocardial infarction (NSTEMI) have improved markedly because of a combination of rapid recognition of the myocardial infarction (MI) event, early invasive management with revascularization, and aggressive secondary prevention treatment strategies. Previous studies have demonstrated differential short-and long-term mortality risks by MI classification (STEMI versus NSTEMI). 1-4 Although patients presenting with STEMI have been demonstrated to have a higher risk of early mortality, 4 patients presenting with NSTEMI have been shown to have a higher risk of long-term mortality that has been attributed to the higher burden of comorbidities and a greater prevalence of multivessel coronary disease in these patients. 1 Notwithstanding these findings, most studies that observed differential risks of long-term outcomes between STEMI and NSTEMI patients included younger populations of patients Background-Among older patients with acute myocardial infarction (MI), it remains uncertain whether there is a timedependent difference in the risk of recurrent mortality and nonfatal cardiovascular and cerebrovascular events for those with ST-segment-elevation MI (STEMI) compared with those with non-ST-segment-elevation MI. Methods and Results-Older patients ≥65 years with acute MI and significant coronary artery disease identified with coronary angiography from the ACTION Registry-GWTG (Get With the Guidelines) were linked to Medicare claims data from 2007 to 2010. We examined the unadjusted cumulative incidence of each outcome studied from hospital discharge through 2 years with log-rank tests and then performed a piece-wise proportional hazards modeling with 2 time periods: discharge to 90 days and 90 days to 2 years. Among the 46 199 patients linked with Medicare data, 17 287 (37.4%) presented with STEMI. Through 2 years, the unadjusted cumulative incidence of all-cause mortality (16.0% versus 19.8%; P<0.001) and the composite outcome (21.9% versus 27.9%; P<0.001) was lower for STEMI patients. Within the first 90 days, unadjusted rates of mortality (5.5% versus 5.3%) and the composite outcome (7.9% versus 8.1%) were similar but diverged from 90 days to 2 years (mortality, 11.1% versus 15.4%; P<0.001; composite outcome, 15.2% versus 21.5%; P<0.001). After multivariable adjustment, the adjusted risks of mortality and the composite outcome through 90 days were higher for STEMI patients, whereas risks of mortality and the composite outcome were attenuated from 90 days through 2 years. Conclusions-Among older acute MI patients with angiographically confirmed coronary artery disease discharged alive, STEMI patients (compared with non-ST-segment-elevation MI patients) were found to have a lower frequency of unadjusted postdischarge mortality and composite cardiovascular and cerebrovascular outcomes through 2 years after hospital discharge. This analysis provides unique insight into differential short-and long-term risks of ischemic cardiovascular and cerebrovascular outcomes by MI classification among older MI patients with confirmed coronary artery disease surviving to hospital discharge. (Circ Cardiovasc Qual Outcomes. 2016;9:513-522.
who were enrolled in randomized clinical trials, which are typically not representative of the diverse and older population of acute MI patients treated in routine clinical practice. [5] [6] [7] [8] Furthermore, the widespread use of urgent coronary angiography and primary percutaneous coronary intervention (PCI) for patients with STEMI treated in routine practice compared with the more selective, risk-based decision-making that underlies the comparatively lower use of coronary angiography and revascularization for NSTEMI patients introduces unavoidable biases that confound the characterization of longterm outcomes between STEMI versus NSTEMI patients. 9 Therefore, to study a homogeneous, older group of STEMI versus NSTEMI patients treated in routine practice, we linked patients with acute MI included in the National Cardiovascular Data Registry ACTION Registry-Get With the Guidelines (GWTG) found to have significant coronary artery disease (CAD) during coronary angiography with Medicare claims data to investigate differential risks of mortality and nonfatal cardiovascular and cerebrovascular outcomes by MI classification.
Methods

Data Source and Study Population
The ACTION Registry-Get With the Guidelines (GWTG) is the largest nationwide registry of acute MI in the United States, and it captures detailed clinical information on consecutive patients presenting with STEMI and NSTEMI at participating centers. Details of the design and conduct of this registry, a collaboration between the American College of Cardiology and the American Heart Association, have been described previously. 10, 11 The registry is regularly and rigorously audited for data completeness and accuracy. 12 Each hospital's institutional review board approved participation in the registry, and the requirement for individual informed consent was waived because data are collected without individual patient identifiers.
We linked patients ≥65 years admitted from January 2, 2007, to December 31, 2010, with Medicare claims data using 5 indirect identifiers in combination (date of birth, sex, hospital ID, date of admission, and date of discharge) using a previously validated data linkage method. 13 In the linked database, we started with 74 798 patients ≥65 years of age who presented with either STEMI or NSTEMI to 504 participating hospitals, underwent coronary angiography, and had been enrolled in Medicare fee-for-service Parts A and B plans for at least 1 year prior the index MI hospitalization. To study a more homogenous population focusing on patients with significant CAD and to avoid the challenges introduced by different patterns of use of angiography and revascularization for STEMI versus NSTEMI, we included only patients who underwent coronary angiography and were found to have significant CAD with at least one coronary stenosis in a major epicardial vessel >50%. Because we were unable to capture the remainder of the in-hospital data for patients after they were transferred out of ACTION-participating hospitals, we excluded patients who were treated at hospitals without PCI capabilities (n=2976). We further excluded patients who did not undergo angiography or had insignificant coronary disease (all lesions ≤50%) on angiography (n=21 490) during the index hospitalization, those who died during the index hospitalization because we chose to focus on postdischarge outcomes (n=2816; 58% STEMI), and those with missing in-hospital revascularization information (n=50; Figure 1 ). Additionally, we excluded nonindex admissions for patients with multiple records (n=1267).
Outcomes and Definitions
We evaluated postdischarge outcomes, including all-cause mortality, rehospitalization for MI, rehospitalization for stroke, and a composite cardiovascular end point comprising death, rehospitalization for MI, or rehospitalization for stroke. All-cause mortality was ascertained from the Medicare denominator file. Cause-specific rehospitalizations for MI and for stroke were ascertained and classified from the primary diagnosis code of the Medicare Part A inpatient claim using the International Classification of Disease, Ninth Revision, Clinical Modification diagnosis codes for MI (410. x1) and for stroke (433.x1, 434.x1, 997.02, 436, 437.1, 437.9, 430, 431, 432.x). 3
Statistical Analyses
We compared baseline demographic, clinical, and presentation characteristics during the index hospitalization between STEMI and NSTEMI patients. Data are expressed as median values with 25th and 75th percentiles for continuous variables and proportions for categorical variables. We compared differences in characteristics between STEMI and NSTEMI patients using Wilcoxon rank-sum tests for continuous variables and Pearson χ 2 tests for categorical variables.
We examined the unadjusted cumulative incidence of each outcome studied from hospital discharge through 2 years with log-rank tests, using Gray's method to account for mortality as a competing risk for nonfatal outcomes. 14 Because the assumption of proportional hazards was not met over the 2-year time frame, we performed a piece-wise proportional hazards model with 2 time periods: from hospital discharge to 90 days and from 90 days to 2 years (using NSTEMI patients as the reference group). We chose the 90-day time point for several reasons. First, the objective of this analysis was not to estimate or emphasize a specific change point but to provide
WHAT IS KNOWN
• Patients presenting with ST-segment-elevation myocardial infarction (STEMI) are known to have a higher risk of early mortality, but patients presenting with non-ST-segment-elevation myocardial infarction have been shown to have a higher risk of long-term mortality, attributed to a higher burden of comorbidities. • However, it is unclear if this extends to older patients with documented coronary artery disease on coronary angiography.
WHAT THE STUDY ADDS
• In a population of older patients presenting with acute myocardial infarction and found to have significant coronary artery disease on coronary angiography, STEMI patients were similar in age but had significantly lower comorbidity than non-ST-segment-elevation myocardial infarction patients. They were more likely to present with a larger infarct and had higher predicted in-hospital mortality. • The unadjusted cumulative incidence of all-cause mortality and a composite outcome, including mortality and nonfatal cardiovascular and cerebrovascular outcomes, was lower for STEMI patients from hospital discharge through 2 years. • After multivariable adjustment, outcomes are worse among STEMI patients within the first 90 days after discharge, but from 90 days to 2 years, risks are similar between STEMI and non-ST-segment-elevation myocardial infarction patients.
perspective on the differences in short-and long-term outcomes by MI type in this population. Second, prior analyses in randomized trials focusing on the post-MI population have demonstrated an increased event rate in the first 90 days compared with beyond. 15, 16 Additionally, we felt that the 90-day time point was important from a care delivery perspective because there may be significant implications for payers and providers during a transition to bundled payment schemes. We adjusted for within-hospital clustering to account for patients being treated at the same hospital having similar treatment compared with patients treated at other hospitals. 17 Outcomes were adjusted for the following variables in our Cox proportional hazards model: demographics (age, sex, body mass index, race), prior medical history (hypertension, diabetes mellitus, dyslipidemia, current/ recent smoker, prior MI, prior heart failure, prior PCI, prior coronary artery bypass grafting, and prior stroke), presentation characteristics (heart rate, systolic blood pressure, presence of heart failure, and presence of cardiogenic shock), laboratory results (baseline hemoglobin [g/dL] and baseline serum creatinine [mg/dL]), and other factors (comorbidity index and in-hospital revascularization). 18 Rates of missingness of covariates was <1% (except for troponin, which was 2.1%), and missing values of continuous variables were imputed using the sex/STEMI-specific median, whereas missing categorical variables were imputed to the most common value. We observed no missingness for STEMI/NSTEMI status or for outcomes. The percent and number of missing patient characteristics are shown in Tables I and II in the Data Supplement. As a sensitivity analysis, we also examined the unadjusted cumulative incidence and adjusted hazard within the first 30 days after discharge and from 30 days to 2 years (with a similar piece-wise analysis) to evaluate for this earlier time frame that has typically been studied in randomized clinical trials that included both STEMI and NSTEMI patients and that is used as a benchmark to evaluate and compare hospital-level postdischarge mortality rates for Medicare-eligible patients with acute MI in the United States. 19 Statistical significance was defined as P<0.05. All analyses were performed by the National Cardiovascular Data Registry data analysis center at the Duke Clinical Research Institute using SAS software (version 9.3, Cary, NC).
Results
Baseline Clinical Characteristics
In our study population of 46 199 older MI patients with significant CAD who survived the index hospitalization and were discharged to home, 17 287 (37.4%) presented with STEMI and 28 912 presented with NSTEMI. Although the median age (75 years) and proportion of female patients (41%) were similar for STEMI versus NSTEMI patients, NSTEMI patients were more likely to have a prior history of MI, heart failure, revascularization (PCI or coronary artery bypass grafting), stroke, peripheral artery disease, hypertension, diabetes mellitus, comorbidities, and heart failure on presentation compared with STEMI patients (Table 1 ). In contrast, STEMI patients were more likely to present with cardiogenic shock.
In-Hospital Treatments, Procedures, and Nonfatal Outcomes
Patients with STEMI were more likely to have single-vessel disease identified during coronary angiography, whereas NSTEMI patients were more likely to have multivessel disease (Table 2 ). Furthermore, PCI was more commonly performed for STEMI patients, whereas coronary artery bypass grafting and medical management were more commonly used for NSTEMI patients. STEMI patients were found to have larger peak troponin and peak CK-MB values and were more likely to have in-hospital heart failure, major bleeding, and cardiogenic shock compared with NSTEMI patients.
Discharge Care Processes
STEMI patients were more likely to receive all classes of evidence-based secondary prevention medications and †The Charlson comorbidity index comprises 12 chronic conditions and corresponding weights (range, 0-6) according to their association with 1-year mortality. 20 ‡Creatinine clearance was calculated by the Cockroft-Gault equation among patients not receiving dialysis. 
Unadjusted Outcomes
From hospital discharge through 2 years, the cumulative incidence rates of all outcomes, including mortality, were lower for STEMI patients (Figure 2 ). There were 2143 deaths in the STEMI group versus 4229 deaths in the NSTEMI group (16.0% versus 19.8%; P<0.001). Rates of rehospitalization for MI (6.1% versus 9.6%; P<0.001), rehospitalization for stroke (2.7% versus 3.2%; P=0.006), and the composite end point (21.9% versus 27.9%; P<0.001) were lower among STEMI patients compared with NSTEMI patients, respectively. Because the assumptions of proportional hazards were not met, we performed a landmark analysis with 90 days as the time point for piecewise analyses comparing 2-year outcomes between STEMI and NSTEMI patients. Cumulative incidence curves through the first 90 days are shown in Figure 3 . There were 929 deaths among STEMI patients and 1475 deaths among NSTEMI patients in the first 90 days (5.5% versus 5.3%; P=0.18; Table 3 ). Rates of rehospitalization for MI (2.1% versus 2.8%; P<0.001) were lower among STEMI patients, whereas the rates of rehospitalization for stroke (0.8% versus 0.7%; P=0.70) and the composite end point (7.9% versus 8.1%; P=0.52) were similar between STEMI and NSTEMI patients. From 90 days to 2 years, the unadjusted rates of all end points are lower among STEMI patients compared with NSTEMI patients (Figure 4 ).
Adjusted Risk of Outcomes
After adjustment for differences in baseline clinical characteristics, STEMI patients were found to have an increased risk of mortality (hazard ratio 1.52, 95% confidence interval 1.38-1.68) and composite outcome (hazard ratio 1.39, 95% confidence interval 1.29-1.50) in the first 90 days compared with NSTEMI patients (Table 3) . Piece-wise analyses from 90 days to 2 years showed higher risk of mortality (hazard ratio 1.10, Figure 2 . Unadjusted long-term outcomes. Each curve represents the cumulative incidence of the respective outcome from hospital discharge through 2 years. The red line represents patients presenting with STEMI, and the blue line represents patients presenting with NSTEMI. Note that the scale is different for each outcome. All-cause mortality (A); readmission for MI (B); readmission for stroke (C); and composite outcome (D). MI indicates myocardial infarction; NSTEMI, non-ST-segment-elevation myocardial infarction; and STEMI, ST-segment-elevation myocardial infarction. 95% confidence interval 1.02-1.18), but this was attenuated compared with the first 90 days; there were no differences in any of the other cardiovascular outcomes evaluated. As a sensitivity analysis, we also examined the unadjusted cumulative incidence and adjusted hazards for the outcomes studied from discharge through the first 30 days and from 30 days to 2 years. The results of this sensitivity analysis were similar to the primary results using the 90-day benchmark ( Table III in the Data Supplement).
Discussion
In a contemporary population of older patients with acute MI found to have significant coronary disease during in-hospital angiography, we observed that STEMI patients had lower unadjusted rates of mortality and composite cardiovascular and cerebrovascular outcomes from hospital discharge through 2 years at all time points, but these differences were accentuated after 90 days. We also found that STEMI patients more frequently underwent PCI during the index hospitalization, were more likely to be discharged on evidence-based medications, and were more likely to undergo lifestyle modification interventions. These findings suggest differential, time-dependent risks of mortality and nonfatal cardiovascular and cerebrovascular outcomes by MI classification among older acute MI patients with confirmed CAD treated in routine practice.
Previous studies have demonstrated significant patient differences by MI classification. A previous single-center analysis demonstrated that STEMI patients were generally younger and had significantly fewer comorbidities compared with NSTEMI patients but had larger infarct sizes. 1 In that analysis, STEMI patients were at increased risk of mortality within 2 months of the index catheterization, but a lower mortality risk was observed after 2 months compared with NSTEMI patients. Our analysis complements and extends that analysis in several ways. First, by focusing on an exclusively Medicare-eligible population, we have muted age differences between the 2 MI classification groups that confound outcomes comparisons between STEMI versus NSTEMI patients. Second, because there is wider Figure 3 . Unadjusted short-term outcomes. Each curve represents the cumulative incidence of the respective outcome from hospital discharge through 90 days. The red line represents patients presenting with STEMI, and the blue line represents patients presenting with NSTEMI. Note that the scale is different for each outcome. All-cause mortality (A); readmission for MI (B); readmission for stroke (C); and composite outcome (D). MI indicates myocardial infarction; NSTEMI, non-ST-segment-elevation myocardial infarction; and STEMI, ST-segment-elevation myocardial infarction. variability in these use of coronary angiography for NSTEMI compared with STEMI patients, our study only included patients who underwent coronary angiography and were found to have obstructive coronary disease to minimize confounding related to the higher use of revascularization procedures (that follow angiography) in STEMI patients. By specifically excluding patients with nonobstructive CAD on angiography, we also further refined our population to be more homogenous to facilitate a likewise comparison between the NSTEMI and STEMI populations. Finally, our analysis focused on a diverse, nationwide, unselected population of older patients with acute MI treated in contemporary practice and demonstrated slightly lower rates of mortality and other outcomes in STEMI versus NSTEMI patients during the first 90 days with a paradoxical higher adjusted risk during this early time frame.
There are several possibilities for the differential outcomes we observed by MI classification. In our study population, NSTEMI patients were found to have a greater likelihood of prior ischemic events, prior revascularization procedures, prior heart failure, comorbidities, and multivessel disease on angiography compared with STEMI patients. These differences, as well as the higher use of a medical management strategy (without revascularization) among NSTEMI patients, likely contributed to the higher unadjusted frequency of long-term ischemic outcomes observed in NSTEMI patients. Furthermore, despite the documentation of significant coronary disease on angiography for all patients studied, NSTEMI patients were less likely to receive evidence-based discharge medications and lifestyle modification interventions, so these treatment differences likely influenced the longer-term outcomes that were evaluated. A previous analysis from the National Registry of Myocardial Infarction 4 (NRMI-4) ≈2 decades ago reported less frequent use of evidence-based medications and lifestyle modifications among patients with NSTEMI versus STEMI, so these treatment disparities have persisted despite national quality improvement initiatives for acute MI. 1, 4 Finally, the larger peak cardiac marker values in STEMI versus NSTEMI patients represent larger infarct sizes (with more myocardium at risk) that coupled together with the greater frequency of cardiogenic shock in STEMI patients and likely contributed to the higher adjusted risks of shortterm outcomes through 90 days in STEMI versus NSTEMI patients. Notwithstanding these possible contributing factors, the adjusted risk of long-term outcomes were similar for STEMI versus NSTEMI patients-a finding that emphasizes the uniform downstream consequences of an acute MI event, regardless of MI classification.
Our study also highlights the importance of studying longterm outcomes among an elderly population of patients with acute MI. Elderly patients are typically under-represented in clinical trials, 21, 22 and there is a paucity of high-quality data to inform practice guidelines in this population. 23, 24 There are also limited data from routine practice on the difference in clinical outcomes among elderly patients by MI classification. [25] [26] [27] A previous analysis focusing on NSTEMI patients from the CRUSADE Registry (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guideline) reported high rates of mortality and nonfatal cardiovascular outcomes among elderly patients through 5 years, regardless of the management strategy, but patients with STEMI were not routinely included in this registry. 4 Our results, therefore, provide valuable insights into the trajectory and occurrence of ischemic outcomes among elderly acute MI patients who were stratified by MI classification and may inform sample size calculations for future secondary prevention clinical trials of patients with acute MI. The proportion of patients included in a randomized trial with STEMI versus NSTEMI is often prespecified, but has varied from 26% to 46% in recent trials that evaluated long-term therapies in the post-MI setting. [6] [7] [8] Further delineation of the specific risks associated with STEMI versus NSTEMI, especially among older acute MI patients, will be useful for more precise determination of sample sizes and power calculations for future long-term clinical trials that enroll patients with a recent acute MI.
Our results also have important implications for patients, providers, payers, and policymakers. For patients and providers, our analysis is a systematic examination of short, intermediate, and long-term outcomes in patients with <0.0001
The composite cardiovascular end point included death, rehospitalization for MI, or rehospitalization for stroke. CI indicates confidence interval; HR, hazard ratio; MI, myocardial infarction; NSTEMI, non-ST-segment-elevation myocardial infarction; and STEMI, ST-segment-elevation myocardial infarction.
angiographically confirmed CAD surviving to hospital discharge and may provide useful context for shared decisionmaking with respect to prognosis post-MI. Our results also have important implications for payers and policymakers during the transition to alternative payment models for acute MI. Under the Bundled Payments for Care improvement initiative by the Center for Medicare and Medicaid Innovation, one proposed payment scheme involves a bundled payment for an episode of care that includes the costs associated with the acute inpatient stay and ≤90 days of care after discharge. The proposed model includes all acute MI patients but does not differentiate between STEMI and NSTEMI patients. Our results demonstrate significant heterogeneity in event rates to 2 years by MI type, and this may have significant implications because payers and providers set rates for bundled care. Although currently proposed bundles extend to 90 days, a time point at which we observe similar unadjusted rates of outcomes, our study suggests that it may be important to stratify by MI type if future proposals consider extending the time frame past 90 days.
There are numerous limitations for our study that deserve consideration. First, our analysis relies on Centers for Medicare and Medicaid Services administrative data to capture data regarding cause-specific rehospitalizations for nonfatal cardiovascular outcomes because traditional end point adjudication was not logistically possible in an observational analysis. The cumulative incidences of these nonfatal outcomes that we report are, thus, not directly comparable with event rates from randomized clinical trials. Second, because we chose to focus on patients presenting with acute MI found to have significant coronary disease during in-hospital angiography and who survived to discharge, our results do not apply to acute MI patients who were managed conservatively without angiography, to those with insignificant coronary disease, and to those who die during the index hospitalization. Third, we were unable to assess long-term adherence to secondary prevention medications prescribed at hospital discharge. Fourth, the use of administrative claims data to ascertain and classify nonfatal cardiovascular and cerebrovascular outcomes may be questioned, but recent analyses demonstrated a high degree of concordance of this Unadjusted outcomes from 90 days to 2 years. Each curve represents the cumulative incidence of the respective outcome from 90 days to 2 years. The red line represents patients presenting with STEMI, and the blue line represents patients presenting with NSTEMI. Note that the scale is different for each outcome. All-cause mortality (A); readmission for MI (B); readmission for stroke (C); and composite outcome (D). MI indicates myocardial infarction; NSTEMI, non-ST-segment-elevation myocardial infarction; and STEMI, ST-segmentelevation myocardial infarction. methodology with traditional cardiovascular end point ascertainment and adjudication that is typically used in randomized clinical trials. 28, 29 Additionally, after the recent standardization of cardiovascular end point events in clinical trials 30 and the likelihood that the vast majority of patients presenting with acute MI or stroke will be hospitalized, the use of administrative claims data to classify cardiovascular outcomes with coding algorithms to confirm cause-specific hospitalizations may be increasingly used in randomized clinical trials. However, details regarding cause of death and subclassification of MI events (Type I-IV by the Universal MI Definition 31 ) cannot be ascertained with administrative claims data. Sixth, the prevalence of Caucasian race in our population is higher than in the general Medicare population-a finding that likely represents the nature of voluntary hospital participation in the ACTION Registry-GWTG. Finally, because this is an observational analysis, we cannot exclude the possibility of unmeasured confounding, nor are we able to draw causal inferences from these results.
Conclusions
In a contemporary population of older patients presenting with acute MI with significant CAD and discharged alive, STEMI patients (compared with NSTEMI patients) were found to have a lower frequency of unadjusted postdischarge mortality and composite cardiovascular and cerebrovascular outcomes through 2 years after hospital discharge. After multivariable adjustment, STEMI patients were at higher risk for events within the first 90 days with attenuated risk from 90 days to 2 years, though these results should be considered hypothesis generating. Thus, this analysis provides unique insight into the time-dependent occurrence of ischemic cardiovascular and cerebrovascular outcomes by MI classification among older acute MI patients with confirmed CAD surviving to hospital discharge.
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